A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Antineoplastics (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Puhe Pharmaceutical Technology
Most Recent Events
- 04 Apr 2023 Planned initiation date changed from 31 Mar 2023 to 1 May 2023.
- 20 Mar 2023 New trial record